Findings represent major and essential step toward future human clinical trials
Led by researchers at University of California San Diego School of Medicine, a diverse team of neuroscientists and surgeons successfully grafted human neural progenitor cells into rhesus monkeys with spinal cord injuries. The grafts not only survived, but grew hundreds of thousands of human axons and synapses, resulting in improved forelimb function in the monkeys.
The findings, published online in the February 26 issue of Nature Medicine, represent a significant step in translating similar, earlier work in rodents closer to human clinical trials and a potential remedy for paralyzing spinal cord injuries in people.
“For more than three decades, spinal cord injury research has slowly moved toward the elusive goal of abundant, long-distance regeneration of injured axons, which is fundamental to any real restoration of physical function,” said Mark Tuszynski, MD, PhD, professor of neuroscience and director of the UC San Diego Translational Neuroscience Institute.
“While there was real progress in research using small animal models, there were also enormous uncertainties that we felt could only be addressed by progressing to models more like humans before we conduct trials with people,” Tuszynski said.
“We discovered, for example, that the grafting methods used with rodents didn’t work in larger, non-human primates. There were critical issues of scale, immunosuppression, timing and other features of methodology that had to be altered or invented. Had we attempted human transplantation without prior large animal testing, there would have been substantial risk of clinical trial failure, not because neural stem cells failed to reach their biological potential but because of things we did not know in terms of grafting and supporting the grafted cells.”
Gregoire Courtine, PhD, a professor and investigator at the Center for Neuroprosthetics and at the Brain Mind Institute, both part of the Swiss Federal Institute of Technology (EPFL) in Geneva, also conducts research seeking to restore function after spinal cord injury. He underscored the importance of the new findings.
“Dr. Tuszynski and his collaborators overcame a number of methodological difficulties specific to primates to obtain this breakthrough,” he said. “Direct translation of their work to humans would have failed, and yet too many studies are bypassing vital translational work in primate models that is necessary before human clinical trials.”
Successfully growing and proliferating functional grafted stem cells in spinal cord injuries is hindered by a multitude of innate, biological challenges. For example, the region surrounding the injury site — the so-called extracellular matrix — inhibits growth in the same way that a superficial scar never resembles the original tissue in form or function. The injury site is abundant with inhibitory myelin proteins (used to make the insulating sheath around many nerve fibers) but lacks growth-promoting factors, such as neurotrophins, that would encourage regeneration of nerve cells’ axons and synapses.
Previous work by Tuszynski and others have found solutions or work-arounds for many of these obstacles, reporting notable progress using rodent models. The new work involves the use of human spinal cord-derived neural progenitor cells (NPCs) — stem cells destined to become nerve cells in the central nervous system (CNS) — in rhesus monkeys, whose biology and physiology is much more similar to humans. Because the NPCs were derived from an 8-week-old human embryonic spinal cord, they possessed active growth programs that supported robust axon extension and appeared to be insensitive to inhibitors present in the adult CNS.
Two weeks after the initial injury (a period intended to represent the time required for an injured person to medically stabilize undergoing neural stem cell therapy), researchers grafted 20 million NPCs into the injury lesions in the monkeys, supported by a cocktail of growth factors and immune suppression drugs.
The work was done at the California National Primate Research Center at UC Davis. Most of the investigators are from UC campuses. “This highly complex translational project shows the value of collaborative research across UC campuses with unique facilities,” said co-author Michael Beattie, PhD, professor and director of research at the Brain and Spinal Injury Center at UC San Francisco.
Over the next nine months, the grafts grew, expressing key neural markers and sending hundreds of thousands of axons — the fibers through which nerve cells conduct signals to other nerve cells — through the injury site to undamaged cells and tissue on the other side. Several months into the study, researchers noted that the monkeys began to display partial recovery of movement in their affected forelimbs.
Notably, the team documented regeneration of corticospinal axons, which are essential for voluntary movement in humans, into the lesion sites — the first such known documentation in a primate model.
Courtine at EPFL, who was not involved in the study, said the findings challenge decades of work on the mechanisms of regeneration failure and “definitely represent a landmark in regeneration medicine.” Nonetheless, he noted that the degree of functional improvement remained limited. “It is not surprising given that the functional integration of new cells and connections into the operation of the nervous system would require time and specific rehabilitation procedures,” he said.
“It’s possible that given a longer period of observation, greater recovery may have occurred,” said the study’s first author, Ephron S. Rosenzweig, PhD, an assistant adjunct professor in Tuszynski’s lab. “Axon regeneration, synapse formation, myelination — these all take time, and are critical for neural function. Grafts, and the new circuitry they were part of, were still maturing at the end of our observations, so it seems possible that recovery might have continued.”
Tuszynski said work remains to be done before initiating human clinical trials, including production of a candidate neural stem cell line from humans that meets requirements of the Food and Drug Administration, and additional studies of safety. His group also continues to explore ways to further enhance the growth, distance and functionality of the regenerated cells.
“We seem to have overcome some major barriers, including the inhibitory nature of adult myelin against axon growth,” he said. “Our work has taught us that stem cells will take a long time to mature after transplantation to an injury site, and that patience will be required when moving to humans. Still, the growth we observe from these cells is remarkable — and unlike anything I thought possible even ten years ago. There is clearly significant potential here that we hope will benefit humans with spinal cord injury.”
The Latest on: Spinal cord injuries
via Google News
The Latest on: Spinal cord injuries
- Spinal Cord Stimulators Market is projected to be valued around US$ 5.17 billion in 2032on July 29, 2022 at 5:45 am
In terms of value, an impressive 6.4% CAGR is estimated for the global spinal cord stimulators market by a report of Future Market Insights (FMI). In 2017, the market will account for nearly US$ 2,000 ...
- Researchers discover neural plastic changes that improve functional recovery after cervical spinal cord injuryon July 19, 2022 at 9:37 am
Spinal cord and brain injury researchers at Indiana University School of Medicine are studying new alternatives to promote functional recovery after a spinal cord injury.
- Experimental Cancer Drug Regrows Nerves in Spinal Cord Injuryon July 19, 2022 at 9:34 am
An experimental cancer drug can regenerate damaged nerves following spinal trauma in mice and rats. The corresponding report was published in Clinical | Drug Discovery And Development ...
- Could an Experimental Cancer Drug Help Treat Spinal Injury?on July 18, 2022 at 4:34 am
That system sometimes activates in response to common cancers and also spinal cord injury. Study co-author Zubair Ahmed, a professor of neuroscience in the Institute of Inflammation and Aging at ...
- Could an Experimental Cancer Drug Help Treat Spinal Injury?on July 18, 2022 at 3:51 am
A drug in development as a cancer therapy may also help the body regenerate damaged nerves after spinal injuries, new research suggests.
- Cancer drug triggers remarkable recovery from spinal cord injury in miceon July 12, 2022 at 5:00 pm
The authors of the new study hypothesize that the activation of this system may slow or prevent recovery from spinal cord injury, by hampering nerve repair. The thinking was that by using AZD1390 ...
- Acute Spinal Cord Injury Market is Anticipated to Register Higher CAGR through Forecast Periodon July 11, 2022 at 6:25 am
Acute Spinal Cord Injury Market Share: Las Vegas, United States: Straits Research’s latest report on, Acute Spinal Cord Injury Market – Global Industry Overview and Forecast 2022-2030 ...
- Spinal Trauma Devices Market is Driven by Increasing Number of Spinal Cord Injuries and Road Accidents, The Insight Partnerson July 11, 2022 at 5:41 am
The spinal trauma devices are used to treat the damage caused to the spinal cord. The damage caused can be temporary or permanent and often leads to loss of sensation, muscle function, or autonomic ...
- Acute Spinal Cord Injury Market Size, Share, Revenue, Segment and Forecast to 2028on July 10, 2022 at 9:29 pm
Jul 11, 2022 (Heraldkeepers) -- An outstanding Acute Spinal Cord Injury market research report provides top to bottom assessment of the market with respect to income and developing business sector.
- Could a Biomaterial Hydrogel One Day Treat Spinal Cord Injuries?on July 7, 2022 at 5:00 pm
Spinal cord injuries or disease are often devastating, leading to significant impairment, pain, and paralysis. While rehabilitation shortly after injury may restore some patients’ mobility, and ...
via Bing News